Evidence map›Paper›PMID 29719626›Full record

ArticleOncotarget2018

Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library.

Sohei Kobayashi, Takaki Hiwasa, Takahiro Arasawa, Akiko Kagaya, Sayaka Ishii, Hideaki Shimada, Masaaki Ito, Masae Suzuki, Masayuki Kano, Bahityar Rahmutulla and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Kelch-like proteins in the gastrointestinal tumors.Acta pharmacologica Sinica · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Sohei KobayashiDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Takaki HiwasaDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Takahiro ArasawaDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Akiko KagayaDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Sayaka IshiiDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Hideaki ShimadaDepartment of Gastroenterological Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan.
Masaaki ItoDepartment of Gastroenterological Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan.
Masae SuzukiDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Masayuki KanoDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Bahityar RahmutullaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Kouichi KitamuraDepartment of Laboratory Medicine & Division of Clinical Genetics and Proteomics, Chiba University Hospital, Chiba 260-8670, Japan.
Yuji SawabeDepartment of Laboratory Medicine & Division of Clinical Genetics and Proteomics, Chiba University Hospital, Chiba 260-8670, Japan.
Hideo ShinDepartment of Neurosurgery, Higashi Funabashi Hospital, Chiba 274-0065, Japan.
Masaki TakiguchiDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Fumio NomuraDivisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan.
Hisahiro MatsubaraDepartment of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Kazuyuki MatsushitaDepartment of Laboratory Medicine & Division of Clinical Genetics and Proteomics, Chiba University Hospital, Chiba 260-8670, Japan.
Chiba University · JPChiba University Hospital · JPToho University · JPFunabashi Orthopaedic Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study was planned to identify novel serum antibody markers for digestive organ cancers. We have used screening by phage expression cloning and identified novel fourteen antigens in this experiment. The presence of auto-antibodies against these antigens in serum specimens was confirmed by western blotting. As for auto-antibodies against fourteen antigens, AlphaLISA (amplified luminescence proximity homogeneous assay) assay was performed in the sera of gastrointestinal cancers patients to confirm the results. Serum antibody levels against these fourteen recombinant proteins as antigens between healthy donors (HD) and esophageal squamous cell carcinoma (ESCC) patients, gastric cancer (GC), or colon cancer (CC) were compared. The serum levels of all fourteen auto-antibodies were significantly higher in ESCC and GC than those of HD. Among those auto-antibodies, except ECSA2 and CCNL2, were also detected significantly higher levels in CC than those of HD. Receiver operating curve (ROC) revealed similar results except CCNL2 in CC. AUC values calculated by ROC were higher than 0.7 in auto-antibodies against TPI1, HOOK2, PUF60, PRDX4, HS3ST1, TUBA1B, TACSTD2, AKR1C3, BAMBI, DCAF15 in ESCC, auto-antibodies against TPI1, HOOK2, PUF60, PRDX4, TACSTD2, AKR1C3, BAMBI, DCAF15 in GC, and auto-antibodies against TPI1, HOOK2, PUF60 in CC. AUC of the combination of HOOK2 and anti-p53 antibodies in ESCC was observed to be as high as 0.8228. Higher serum antibody levels against ten antigens could be potential diagnostic tool for ESCC. Higher serum antibody levels against eight antigens could be potential diagnostic tool for GC, and serum antibody levels against three antigens could be potential diagnostic tool for CC.

Indexed as

AlphaLISAcancer-testis antigenesophageal squamous cell carcinomagastrointestinal cancersSEREX

Identifiers

PMID29719626
PMCPMC5915093
OpenAlexW2795724660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.